Open AccessObjectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
Author(s) -
Clas-Göran af Björkesten,
Tuire Ilus,
Taru Hallinen,
Erkki Soini,
Anja Eberl,
Kristo Hakala,
Mikko Heikura,
Airi Jussila,
Ritva Koskela,
Inka Koskinen,
Veikko Moilanen,
Christian Nielsen,
U Nieminen,
Heikki Nuutinen,
Markku Heikkinen,
Ulla-Maija Suhonen,
Jyrki Tillonen,
Karri Utriainen,
Ilkka Vihriälä,
Christina Wennerström,
András Borsi,
R Nissinen,
M Koivunen,
Taina Sipponen
Publication year - 2020
Publication title -
european journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
eISSN - 1473-5687
pISSN - 0954-691X
DOI - 10.1097/meg.0000000000001831
Subject(s) - medicine , ustekinumab , crohn's disease , cohort , persistence (discontinuity) , disease , crohn disease , cohort study , drug , adalimumab , pharmacology , geotechnical engineering , engineering
Long-term evidence on ustekinumab treatment response and persistence in patients with Crohn's disease in a real-world setting is scarce. We performed a retrospective nationwide chart review study of long-term clinical outcomes in Crohn's disease patients treated with ustekinumab.